Health & Fitness
Health and Fitness
Health and Fitness
Mon, August 16, 2010Fri, August 13, 2010Thu, August 12, 2010Wed, August 11, 2010Tue, August 10, 2010Mon, August 9, 2010Fri, August 6, 2010Thu, August 5, 2010Wed, August 4, 2010Tue, August 3, 2010Mon, August 2, 2010Fri, July 30, 2010Thu, July 29, 2010Wed, July 28, 2010Tue, July 27, 2010Mon, July 26, 2010ZymoGenetics to Webcast Presentation at the Canaccord Annual Growth Conference
Published in Health and Fitness on Wednesday, August 4th 2010 at 4:46 GMT by Market Wire
SEATTLE--([ BUSINESS WIRE ])--ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that Douglas E. Williams, Ph.D., Chief Executive Officer of ZymoGenetics, will present at the Canaccord Annual Growth Conference in Boston on Tuesday, August 10, 2010 at 8:30 a.m. Eastern Time.
A live webcast of the presentation can be accessed by going to: [ www.zymogenetics.com ]. The webcast will be archived for 30 days.
About ZymoGenetics
ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. The company developed and is marketing RECOTHROM® Thrombin, topical (Recombinant) in the United States. ZymoGenetics has two product candidates in Phase 2 clinical development: PEG-Interferon lambda, being studied in collaboration with Bristol-Myers Squibb for treatment of hepatitis C virus infection, and IL-21, being tested as a potential treatment for metastatic melanoma. In addition, ZymoGenetics has an anti-IL-31 monoclonal antibody in preclinical development, which it expects to test initially as a treatment for atopic dermatitis. Several of the product candidates previously identified through ZymoGeneticsa™ discovery research efforts have been licensed to and are being developed by third parties, including Merck Serono and Novo Nordisk. ZymoGenetics is eligible to receive milestone payments and royalties related to these assets. For further information, visit [ www.zymogenetics.com ].
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics.These statements are not guarantees of future actions and involve uncertainties that are difficult to predict. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.
